Exploring NX-5948: A CNS Penetrant Selective Degrader of BTK that Significantly Reduces Inflammation in Mouse Models of Autoimmune Disease

Time: 4:30 pm
day: Day One


  • Uncover NX-5948, a highly potent, CNS penetrant, targeted protein degrader of BTK in Phase 1 clinical development for B cell malignancies
  • Evaluate how daily oral administration of NX-5948 provides efficacy in multiple preclinical models of autoimmune disease
  • Learn how NX-5948 preclinical data supports further exploration of NX-5948 to treat autoimmune diseases